Noom, a leading behavior change company, has announced a new partnership with Liviniti, a digital health platform specialized in diabetes management, to integrate their platforms and provide a comprehensive solution for individuals with type 2 diabetes. This collaboration will bring together Noom’s expertise in behavior change and Liviniti’s focus on personalized diabetes care to create a powerful tool for managing the condition.

The integration of Noom’s behavior change platform with Liviniti’s GLP-1 Companion platform will allow individuals with type 2 diabetes to receive tailored coaching and support in conjunction with their prescribed GLP-1 therapy. This partnership aims to address the full spectrum of diabetes care, including lifestyle management, medication adherence, and overall well-being.

GLP-1 Companion, developed by Liviniti, is designed to support individuals using GLP-1 receptor agonists, a class of medications commonly used to lower blood sugar levels in people with type 2 diabetes. The platform provides personalized insights, reminders, and resources to help individuals better manage their condition and improve their overall health.

By integrating Noom’s behavior change platform with GLP-1 Companion, individuals will have access to a holistic solution that addresses both the physical and behavioral aspects of diabetes management. Noom’s platform uses a combination of cognitive behavioral therapy, personalized coaching, and data-driven insights to help individuals make lasting changes to their health behaviors. This integrated approach will provide individuals with the tools and support they need to effectively manage their diabetes and improve their overall well-being.

The partnership between Noom and Liviniti represents a significant advancement in the field of digital health, particularly for individuals with type 2 diabetes. By combining their respective expertise, these two companies are poised to offer a comprehensive and personalized solution that can significantly impact the lives of those living with diabetes.

In a statement about the partnership, Saeju Jeong, co-founder and CEO of Noom, expressed his enthusiasm for the collaboration, stating, “We are excited to partner with Liviniti to create a comprehensive solution for individuals with type 2 diabetes. By integrating our behavior change platform with Liviniti’s GLP-1 Companion, we can provide individuals with the support and resources they need to successfully manage their condition and improve their overall health.”

This partnership between Noom and Liviniti represents a promising development in the digital health space, particularly for individuals with type 2 diabetes. By leveraging their respective strengths, these two companies have the potential to make a significant impact on the lives of individuals living with this chronic condition. As they work together to integrate their platforms and provide a holistic solution for diabetes management, it is clear that the future of digital health is bright.